Evidence map›Paper›PMID 42593841›Full record

ArticleAngewandte Chemie (International ed. in English)2026

De Novo Discovery of Nonstandard Thioisoindole-Bridged Bicyclic Peptides Targeting Traf2- and NCK-Interacting Kinase.

Yue Zhang, Alexander A Vinogradov, Keisuke Hamada, Yin Sun, Toru Sengoku, Hiroaki Suga

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yue ZhangDepartment of Chemistry, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6807-2084
Alexander A VinogradovDepartment of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore.ORCID https://orcid.org/0000-0002-8899-0533
Keisuke HamadaDepartment of Biochemistry, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.ORCID https://orcid.org/0000-0002-8181-9266
Yin SunDepartment of Chemistry, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Toru SengokuDepartment of Biochemistry, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.ORCID https://orcid.org/0000-0001-9461-8714
Hiroaki SugaDepartment of Chemistry, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5298-9186

Funding

Basis for Supporting Innovative Drug Discovery and Life Science Research JP25ama121001(No.4668)Japan Society for the Promotion of Science 22F22334Japan Society for the Promotion of Science 22KF0114NSFC Young Scientists Fund 22507075NUS Presidential Young Professor program A-0010082-00-00NUS Presidential Young Professor program A-0010082-01-00Specially Promoted Research JP20H05618
6 · The paper itself

Abstract

Macrocyclization strategies that generate conformationally constrained peptide scaffolds within nucleotide-encoded library screening platforms have significantly advanced the discovery of de novo bioactive peptides. We previously reported ribosomal synthesis of topologically defined thioisoindole-bridged bicyclic (TiB) peptides, but complete conversion required overnight incubation. Here, we reengineer the key ribosomally incorporated substrate to accelerate TiB formation to full conversion within 2 h. This was followed by a streptavidin-based pulldown step to efficiently remove linear species and purify the desired TiB peptides. The optimized chemistry was incorporated into the RaPID (Random nonstandard peptides integrated discovery) system to enable de novo identification of TiB peptide ligands. As a proof of concept, two complementary TiB libraries were screened against Traf2- and NCK-interacting kinase (TNIK). Of the five TiB candidates identified, four exhibited nanomolar affinity for TNIK (best K

Indexed as

IndolesPeptidesPeptides, CyclicProtein Kinase InhibitorsProtein Serine-Threonine KinasesTNF Receptor-Associated Factor 2HumansIndolesPeptidesPeptides, CyclicProtein Kinase InhibitorsProtein Serine-Threonine KinasesTNF Receptor-Associated Factor 2TNIK protein, humanmRNA displayPeptide drug discoveryRaPID system

Identifiers

PMID42593841
PMCPMC13638109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.